MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatment

/PRNewswire/ -- Since the June 2022 approval of Eli Lilly's Olumiant (baricitinib), the AA market landscape has been dynamic with two more oral JAK inhibitors...

Related Keywords

Eli Lilly Olumiant ,Pooja Patel ,Pfizer ,Market Research ,Frontal Fibrosing Alopecia ,Alopecia Areata ,Eli Lilly ,Concert Pharmaceutical ,Reach Market Research ,